Melanotan II

Melanotan II, also known as MT-II, is a synthetic cyclic heptapeptide intended exclusively for laboratory, analytical, and scientific research.

It was developed as an analogue of α-MSH and has been studied as a ligand of melanocortin receptors. Its cyclic structure and receptor activity make it useful in experimental research involving melanocortin signaling, peptide chemistry, receptor interactions, and pigmentation-related biological pathways.

Laboratory research involving Melanotan II may include:

• Melanocortin receptor signaling
• α-MSH analogue research
• Pigmentation and melanocyte biology
• Peptide–receptor interaction studies
• Cyclic peptide characterization
• Molecular signaling pathways
• Structure–activity relationship research
• Peptide stability analysis
• Analytical method development
• Comparative peptide research

Product Information

• Product: Melanotan II
• Alternative Name: MT-II
• Classification: Synthetic cyclic heptapeptide
• Research Target: Melanocortin receptor systems
• Primary Research Area: Dermal and pigmentation biology
• Intended Setting: Laboratory, analytical, and scientific research
• Supplier: Peptides R US

FDA’s substance database assigns Melanotan II the identifier UNII UPF5CJ93X7 and lists its molecular formula as C₅₀H₆₉N₁₅O₉. Importantly, FDA states that the presence of a substance in its identification database does not imply regulatory review or approval.

Regulatory / Research Use Notice

This product is offered solely for legitimate laboratory, analytical, and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, tanning, sexual-performance, therapeutic, or clinical-use instructions are provided or implied.

FDA currently identifies compounded products containing Melanotan II as potentially presenting risks involving immunogenicity, aggregation, and peptide-related impurities. FDA has also previously taken enforcement action involving Melanotan II marketed for human use despite “research/laboratory use only” disclaimers.